0001209191-20-034091.txt : 20200603
0001209191-20-034091.hdr.sgml : 20200603
20200603165540
ACCESSION NUMBER: 0001209191-20-034091
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200601
FILED AS OF DATE: 20200603
DATE AS OF CHANGE: 20200603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nash Huw M.
CENTRAL INDEX KEY: 0001780085
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38938
FILM NUMBER: 20940685
MAIL ADDRESS:
STREET 1: C/O STOKE THERAPEUTICS, INC.
STREET 2: 45 WIGGINS AVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Stoke Therapeutics, Inc.
CENTRAL INDEX KEY: 0001623526
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471144582
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 PRESTON COURT
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 781-430-8200
MAIL ADDRESS:
STREET 1: 3 PRESTON COURT
CITY: BEDFORD
STATE: MA
ZIP: 01730
FORMER COMPANY:
FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141028
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-01
0
0001623526
Stoke Therapeutics, Inc.
STOK
0001780085
Nash Huw M.
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
BEDFORD
MA
01730
0
1
0
0
COO & CBO
Common Stock
2020-06-01
4
M
0
2107
2.19
A
2107
D
Common Stock
2020-06-01
4
S
0
1607
27.0823
D
500
D
Common Stock
2020-06-01
4
S
0
500
27.484
D
0
D
Employee Stock Option (Right to Buy)
2.19
2020-06-01
4
M
0
2107
0.00
D
2018-12-12
Common Stock
2107
228711
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.39 to $27.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date.
/s/ Stephen Tulipano, Attorney-in-Fact
2020-06-03